NO.PP.Prepublished online as a Blood First Edition Paper on December 18, 2007; DOI 10.This Article All Versions of this Article: 111/5/2556 _most recent_ Services Citing Articles Google Scholar PubMed Related Collections Social Bookmarking CLINICAL TRIALS AND OBSERVATIONS IMPROVED OUE IN MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS IS ASSOCIATED WITH THERAPY INTENSIFICATION HELMUT GADNER1, NICOLE GROIS1, ULRIKE PTSCHGER1, MILEN MINKOV1, MAURIZIO ARIC2, JORGE BRAIER3, VALERIE BROADBENT4, JEAN DONADIEU5, JAN-INGE HENTER6, ROBERT MCCARTER7, STEPHAN LADISCH7, FOR THE HISTIOCYTE SOCIETY 1 Children's Cancer Research Institute, St Anna Children's Hospital, Vienna, Austria; 2 Pediatric Hematology/Oncology, University of Palermo, Palermo, Italy; 3 Hospital Nacional de Pediatria J.Argentina; 4 Addenbrookes Hospital, Cambridge, United Kingdom; 5 Assistance-Publique Hpitaux de Paris, Hopital Trousseau, Paris, France; 6 Childhood Cancer Research Unit, Department of Women and Child, Karolinska University Hospital, Stockholm, Sweden; and 7 Children's Research Institute, Children's National Medical Center, Washington, DC Multisystem Langerhans cell histiocytosis (MS-LCH) is associated with high mortality when patients have risk organ involvement (RO+) or are younger than 2 years.An international randomized trial, LCH-II, we intensified their treatment: arm A consisted of 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6-mercaptopurine with vinblastine/prednisone pulses; etoposide was added in arm B.All 193 randomized risk patients, there were similar oues: rapid (6 weeks) response (arm A vs arm B: 63%/71%), 5-year survival probability (74%/79%), disease reactivation frequency (46%/46%), and permanent consequences (43%/37%).(1) patients younger than 2 years without RO involvement (RO-) had 100% survival and uniformly high (> 80%) rapid response, (2) RO+ patients not responding within 6 weeks had highest mortality, and (3) importantly, the more intensive arm B reduced mortality in RO+ patients (relative hazard rate, accounting for differences in risk organ involvement, of 0.CI = 0.Finally,parison of RO+ patients in LCH-I and LCH-II confirmed that increasing treatment intensity increased rapid responses (from 43% in arm A LCH-I to 68% in arm B LCH-II; _P_ = .Mortality (from 44% in arm A LCH-I to 27% in arm B LCH-II; _P_ = .We conclude that intensified treatment significantly increases rapid response and reduces mortality in risk MS-LCH.A pre-docking role for microtubules in insulin-stimulated glucose transporter 4 translocation
Sex, race, and smoking impact olanzapine exposure
